×
About 227,390 results

ALLMedicine™ Lung Cancer Center

Research & Reviews  105,123 results

Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung...
https://doi.org/10.1186/s12957-021-02161-1 10.3322/caac.21262 10.3322/caac.21492 10.1126/science.1104819 10.1016/S0065-230X(08)60946-X 10.1200/jco.2004.22.90140.2542 10.1016/0197-2456(95)00134-4 10.1007/s10654-010-9491-z 10.1136/bmj.316.7124.61 10.1515/med-2018-0022 10.1016/j.cllc.2013.12.006
World Journal of Surgical Oncology; Feng L, Wang Z et. al.

Feb 27th, 2021 - This paper aims to compare the efficacy and safety of recombinant human endostatin combined with chemotherapy in patients with squamous cell lung cancer (SqCLC). We searched the Cochrane Library, PubMed, Embase, CNKI, Wanfang database, Metstr, VIP...

Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
https://doi.org/10.1016/j.cllc.2021.01.006
Clinical Lung Cancer; Keiser MF, Patel AB et. al.

Feb 27th, 2021 - Immune checkpoint inhibitors (ICPIs) have transformed the treatment of lung cancer in the recent years. However, disruption in immune homeostasis produces a unique spectrum of side effects termed as immune-related adverse events (irAEs). Cutaneous...

Developing pathways, a hope-enhancing intervention for metastatic lung cancer patients ...
https://doi.org/10.1002/pon.5650
Psycho-oncology McLouth LE, Weyman K et. al.

Feb 27th, 2021 - Between 40% and 65% of lung cancer patients report concern about maintaining valued activities and roles, yet few interventions address this concern. Hope, a patient's perceived ability to generate goals and identify ways to pursue them, may be a ...

Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.
https://doi.org/10.1007/s40265-021-01477-2 10.1016/j.ccm.2011.09.001 10.1038/nrc.2017.84 10.1200/JCO.2015.63.4600 10.3978/j.issn.2218-6751.2012.09.03 10.2741/2760 10.1007/BF00204976 10.1073/pnas.94.21.11445 10.3978/j.issn.2218-6751.2015.03.05 10.1158/2159-8290.CD-19-1446 10.1083/jcb.153.5.1023 10.1158/0008-5472.CAN-05-4422 10.1016/j.jtho.2016.10.014 10.3978/j.issn.2305-5839.2015.03.58 10.1038/nrm1261 10.1200/JCO.2012.47.4189 10.1200/JCO.2016.69.2160 10.1586/14737140.2015.1031219 10.1200/JCO.2014.60.7317 10.1126/science.1141478 10.1016/j.jtho.2016.04.033 10.21037/tlcr-19-339 10.1158/0008-5472.CAN-06-3495 10.1016/j.jtho.2016.09.116 10.1056/NEJMoa2002787 10.1038/sj.onc.1209717 10.1016/j.jtho.2016.06.013 10.1158/2159-8290.CD-15-0285 10.1038/nature13385 10.1158/2159-8290.CD-14-1467 10.1634/theoncologist.2015-0510 10.1097/JTO.0000000000000478 10.1016/j.cllc.2015.01.009 10.1200/JCO.2016.34.15_suppl.108 10.1016/j.ctrv.2020.102022 10.1097/JTO.0000000000000491 10.1038/s41591-019-0716-8 10.1016/j.lungcan.2016.05.015 10.1158/1078-0432.CCR-19-3608 10.1158/1078-0432.CCR-11-1157 10.1200/JCO.2016.34.15_suppl.9067 10.1016/j.annonc.2020.03.293 10.1007/s40265-020-01347-3 10.1200/JCO.2018.36.15_suppl.9016 10.1056/NEJMoa2004407 10.1007/s40265-020-01317-9 10.1158/1538-7445.Am2016-1150 10.1200/JCO.2020.38.15_suppl.9519 10.1016/S1470-2045(19)30785-5 10.1016/j.jtho.2017.09.377 10.1186/s13045-019-0759-9 10.1016/j.jtho.2016.09.127 10.1016/S1470-2045(16)30561-7 10.1038/emm.2017.17 10.3390/biomedicines3010149 10.1158/1078-0432.Ccr-16-1568 10.1158/1078-0432.Ccr-14-0543 10.1158/1538-7445.Am2017-519 10.1158/1078-0432.Ccr-16-1418 10.1016/j.jtho.2019.10.003 10.1158/1535-7163.Targ-09-c181 10.1200/jco.2010.28.15_suppl.2525 10.1002/cpdd.427 10.1016/j.jtho.2017.09.458 10.1200/jco.2018.78.7697
Drugs Garon EB, Brodrick P

Feb 27th, 2021 - The tyrosine kinase receptor mesenchymal epithelial transition (MET) is a proto-oncogene that, through the activation of the MET-hepatocyte growth factor (HGF) pathway, encodes a variety of biological processes, including cell development, prolife...

see more →

Guidelines  587 results

Changes in Black-White Difference in Lung Cancer Incidence among Young Adults
https://academic.oup.com/jncics/article/4/4/pkaa055/5894724?searchresult=1
JNCI Cancer Spectrum; Jemal A

Aug 19th, 2020 - We previously reported that lung cancer incidence between Blacks and Whites younger than 40 years of age converged in women and approached convergence in men. Whether this pattern has continued in contemporary young birth cohorts is unclear.

Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors
https://pubmed.ncbi.nlm.nih.gov/32746691/
Journal of Oncology Pharmacy Practice; Rosentreter J

Aug 2nd, 2020 - Cancer patients tend to prefer oral instead of parenteral chemotherapy. To date, there is little evidence on the medication adherence in cancer patients. We investigated medication adherence to tyrosine kinase inhibitors in patients suffering from...

Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3...
https://www.jto.org/article/S1556-0864(20)30595-5/pdf
Journal of Thoracic Oncology; Yang Y

Jul 24th, 2020 - Sintilimab, an anti-programmed death 1 antibody, plus pemetrexed and platinum had shown promising efficacy for nonsquamous non-small cell lung cancer in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to compare the ef...

Peritumoral and intratumoral radiomic features predict survival outcomes among patients diagnosed in lung cancer screening
https://www.nature.com/articles/s41598-020-67378-8
Scientific Report; Perez-Morales J

Jun 28th, 2020 - The National Lung Screening Trial (NLST) demonstrated that screening with low-dose computed tomography (LDCT) is associated with a 20% reduction in lung cancer mortality. One potential limitation of LDCT screening is overdiagnosis of slow growing ...

Top Lung Cancer Research Presented at the ASCO20 Virtual Scientific Program Has Implications for Clinical Practice
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200223/full/

Jun 24th, 2020 - Although the ASCO Annual Meeting felt much different this year given the virtual format, the quality of research presented at the meeting was undiminished, particularly in the field of lung cancer. ASCO Daily News Expert Panel member Jared Weiss, ...

see more →

Drugs  391 results see all →

Clinicaltrials.gov  114,005 results

Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung...
https://doi.org/10.1186/s12957-021-02161-1 10.3322/caac.21262 10.3322/caac.21492 10.1126/science.1104819 10.1016/S0065-230X(08)60946-X 10.1200/jco.2004.22.90140.2542 10.1016/0197-2456(95)00134-4 10.1007/s10654-010-9491-z 10.1136/bmj.316.7124.61 10.1515/med-2018-0022 10.1016/j.cllc.2013.12.006
World Journal of Surgical Oncology; Feng L, Wang Z et. al.

Feb 27th, 2021 - This paper aims to compare the efficacy and safety of recombinant human endostatin combined with chemotherapy in patients with squamous cell lung cancer (SqCLC). We searched the Cochrane Library, PubMed, Embase, CNKI, Wanfang database, Metstr, VIP...

Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
https://doi.org/10.1016/j.cllc.2021.01.006
Clinical Lung Cancer; Keiser MF, Patel AB et. al.

Feb 27th, 2021 - Immune checkpoint inhibitors (ICPIs) have transformed the treatment of lung cancer in the recent years. However, disruption in immune homeostasis produces a unique spectrum of side effects termed as immune-related adverse events (irAEs). Cutaneous...

Developing pathways, a hope-enhancing intervention for metastatic lung cancer patients ...
https://doi.org/10.1002/pon.5650
Psycho-oncology McLouth LE, Weyman K et. al.

Feb 27th, 2021 - Between 40% and 65% of lung cancer patients report concern about maintaining valued activities and roles, yet few interventions address this concern. Hope, a patient's perceived ability to generate goals and identify ways to pursue them, may be a ...

Targeted Therapy Approaches for MET Abnormalities in Non-Small Cell Lung Cancer.
https://doi.org/10.1007/s40265-021-01477-2 10.1016/j.ccm.2011.09.001 10.1038/nrc.2017.84 10.1200/JCO.2015.63.4600 10.3978/j.issn.2218-6751.2012.09.03 10.2741/2760 10.1007/BF00204976 10.1073/pnas.94.21.11445 10.3978/j.issn.2218-6751.2015.03.05 10.1158/2159-8290.CD-19-1446 10.1083/jcb.153.5.1023 10.1158/0008-5472.CAN-05-4422 10.1016/j.jtho.2016.10.014 10.3978/j.issn.2305-5839.2015.03.58 10.1038/nrm1261 10.1200/JCO.2012.47.4189 10.1200/JCO.2016.69.2160 10.1586/14737140.2015.1031219 10.1200/JCO.2014.60.7317 10.1126/science.1141478 10.1016/j.jtho.2016.04.033 10.21037/tlcr-19-339 10.1158/0008-5472.CAN-06-3495 10.1016/j.jtho.2016.09.116 10.1056/NEJMoa2002787 10.1038/sj.onc.1209717 10.1016/j.jtho.2016.06.013 10.1158/2159-8290.CD-15-0285 10.1038/nature13385 10.1158/2159-8290.CD-14-1467 10.1634/theoncologist.2015-0510 10.1097/JTO.0000000000000478 10.1016/j.cllc.2015.01.009 10.1200/JCO.2016.34.15_suppl.108 10.1016/j.ctrv.2020.102022 10.1097/JTO.0000000000000491 10.1038/s41591-019-0716-8 10.1016/j.lungcan.2016.05.015 10.1158/1078-0432.CCR-19-3608 10.1158/1078-0432.CCR-11-1157 10.1200/JCO.2016.34.15_suppl.9067 10.1016/j.annonc.2020.03.293 10.1007/s40265-020-01347-3 10.1200/JCO.2018.36.15_suppl.9016 10.1056/NEJMoa2004407 10.1007/s40265-020-01317-9 10.1158/1538-7445.Am2016-1150 10.1200/JCO.2020.38.15_suppl.9519 10.1016/S1470-2045(19)30785-5 10.1016/j.jtho.2017.09.377 10.1186/s13045-019-0759-9 10.1016/j.jtho.2016.09.127 10.1016/S1470-2045(16)30561-7 10.1038/emm.2017.17 10.3390/biomedicines3010149 10.1158/1078-0432.Ccr-16-1568 10.1158/1078-0432.Ccr-14-0543 10.1158/1538-7445.Am2017-519 10.1158/1078-0432.Ccr-16-1418 10.1016/j.jtho.2019.10.003 10.1158/1535-7163.Targ-09-c181 10.1200/jco.2010.28.15_suppl.2525 10.1002/cpdd.427 10.1016/j.jtho.2017.09.458 10.1200/jco.2018.78.7697
Drugs Garon EB, Brodrick P

Feb 27th, 2021 - The tyrosine kinase receptor mesenchymal epithelial transition (MET) is a proto-oncogene that, through the activation of the MET-hepatocyte growth factor (HGF) pathway, encodes a variety of biological processes, including cell development, prolife...

see more →

News  7,181 results

FDA Approves Cemiplimab-rwlc for NSCLC With PD-L1 Expression
https://www.medscape.com/viewarticle/946366

Feb 23rd, 2021 - The US Food and Drug Administration (FDA) has approved cemiplimab-rwlc (Libtayo) for the treatment of advanced non–small cell lung cancer (NSCLC). Specifically, the indication is for first-line treatment as monotherapy for patients with locally ad...

Bladder Cancer Indication Withdrawn for Durvalumab
https://www.medscape.com/viewarticle/946293

Feb 22nd, 2021 - After failing to improve overall survival in unresectable metastatic bladder cancer in a phase 3 trial, this indication will be withdrawn in the United States for the immunotherapy durvalumab (Imfinzi), AstraZeneca announced. The withdrawal does n...

Cancer Death Rates Continue to Fall in Europe, Except For...
https://www.medscape.com/viewarticle/946288

Feb 22nd, 2021 - Cancer death rates overall continue to fall among both men and women in Europe, with the notable exception of pancreatic cancer in both sexes and lung cancer among women living in the European Union, notes an update report. "Among the major cancer...

X-ray Vision: Using AI to Maximize the Value of Radiographic Images
https://www.medscape.com/viewarticle/946034

Feb 17th, 2021 - Artificial intelligence (AI) is expected to one day affect the entire continuum of cancer care – from screening and risk prediction to diagnosis, risk stratification, treatment selection, and follow-up, according to an expert in the field. Hugo J....

Rush Limbaugh Dies at 70 Following Lung Cancer Diagnosis
https://www.medscape.com/viewarticle/946016

Feb 16th, 2021 - Feb. 17, 2021 — Rush Limbaugh, for decades a popular, controversial, and influential talk radio host and conservative commentator, died Wednesday, according to a family statement. He was 70.

see more →

Patient Education  103 results see all →